


Investment Objective

The Strategy aims to generate long term capital appreciation by creating a focused portfolio of high growth stocks having the potential to grow more than the nominal GDP for next 5-7 years across and which are available at reasonable market prices.

Performance



Performance Attribution Analysis (1 Year Trailing 30th Jun 2018)

| Scrip | Contribution |
|---|--------------|
| Quess Corp Limited | 1.11% |
| AU Small Finance Bank Limited | 0.41% |
| Aegis Logistics Limited | 0.35% |
| Dr. Lal PathLabs Limited | 0.34% |
| IIFL Holdings Limited | 0.17% |
| Alkem Laboratories Limited | 0.06% |
| VIP Industries Limited | 0.04% |
| SPAISA | 0.01% |
| Dishman Pharmaceuticals & Chemicals Limited | 0.00% |
| V-Mart Retail Limited | -0.01% |
| Glaxosmithkline Consumer Healthcare Limited | -0.02% |
| Bayer CropScience Limited | -0.02% |
| Blue Star Limited | -0.11% |
| Phoenix Lamps Limited | -0.16% |
| Gabriel India Limited | -0.29% |
| Suprajit Engineering Limited | -0.38% |
| T T K Prestige Limited | -0.71% |
| ITD Cementation India Limited | -0.79% |
| Mahanagar Gas Limited | -0.82% |
| Dishman Carbogen Amcis Limited | -0.90% |
| Dhanuka Agritech Limited | -1.03% |
| Birla Corporation Limited | -1.22% |
| Kajaria Ceramics Limited | -1.26% |
| Development Credit Bank Limited | -1.71% |
| Lakshmi Vilas Bank Limited | -2.45% |
| Can Fin Homes Limited | -3.36% |

Holding & Top 5 Sectors

| Scrip Names | % Holdings |
|--|------------|
| Development Credit Bank Ltd | 9.59 |
| AU Small Finance Bank | 8.06 |
| Birla Corporation Ltd. | 7.83 |
| Aegis Logistics Ltd | 6.64 |
| Quess Corp Ltd | 6.50 |
| Gabriel India Limited | 5.75 |
| TTK Prestig | 5.03 |
| Mahanagar Gas Ltd | 4.97 |
| Alkem Laboratories Ltd | 4.93 |
| Canfin Homes Ltd | 4.45 |
| Blue Star Ltd | 4.29 |
| Kajaria Ceramics Ltd | 4.28 |
| Dishman Carbogen Amcis Ltd | 4.24 |
| Lakshmi Vilas Bank Ltd | 4.05 |
| Dr Lal Pathlabs Ltd | 3.95 |
| IIFL Holdings Ltd | 3.07 |
| ITD Cementation India Ltd | 2.77 |
| Dhanuka Agritech Ltd | 2.41 |
| Bayer Cropsience Limited | 2.11 |
| Suprajit Engineering Ltd | 2.03 |
| VIP Industries Ltd | 1.08 |
| Glaxosmithkline Consumer Healthcare Ltd. | 1.06 |
| V-Mart Retail Ltd | 0.88 |
| 5Paisa Capital Ltd | 0.05 |

| Sectors | % Allocation |
|-------------------------|--------------|
| Banking & Finance | 29.22 |
| Pharmaceuticals | 13.11 |
| Oil and Gas | 11.61 |
| Cement & Infrastructure | 10.60 |
| Consumer Durable | 9.30 |
| Cash | 0.00 |

Market Capitalization

| Market Capitalization | % Equity |
|-----------------------|----------|
| Large cap | - |
| Midcap | 34.98 |
| Smallcap | 64.15 |

| | |
|----------------------------------|-----------|
| Weighted Average Market Cap (Rs) | 8,891 Crs |
|----------------------------------|-----------|

Risk Ratios

| 1 Year Data | Scheme | Benchmark |
|------------------|--------|-----------|
| Std Dev | 14.00% | 15.05% |
| Beta | 0.71 | 1.00 |
| Sharpe Ratio | -3.02 | -1.18 |
| Upside Capture | 0.68 | 1.00 |
| Downside Capture | 0.93 | 1.00 |

Portfolio Fundamentals

| | FY18 | FY19E | FY20E |
|------------|-------|-------|-------|
| PAT Growth | 22% | 29% | 28% |
| RoE | 14% | 20% | 21% |
| PE | 36.84 | 27.47 | 21.38 |

Disclaimers and Risk Factors

: IOP Strategy Inception Date: 15th Feb 2010 :: Data as on 30th Jun 2018 :: Data Source: MOAMC Internal Research :: RFR – 7.25% :: *For March 2018 ending quarter
Please Note: The above strategy returns are of a Model Client as on 30th Jun 2018. Returns of individual clients may differ depending on time of entry in the Strategy. Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns below 1 year are absolute and above 1 year are annualized. Strategy returns shown above are post fees & expenses. The stocks forming part of the existing portfolio under IOP Strategy may or may not be bought for new client. Name of the PMS Strategy does not in any manner indicate its future prospects and returns. The Company names mentioned above is only for the purpose of explaining the concept and should not be construed as recommendations from MOAMC